A successful quest

Some 100 years ago, xanthohumol was first isolated and identified. For the last 60 years, scientific research has made remarkable discoveries and gained ever greater insights into its potential as an active agent for health. Throughout the world, numerous universities and research institutes have devoted time and money to investigate the health-enhancing properties of xanthohumol. They have, at this stage, produced an extensive scientific literature on the subject (over 400 papers and articles).

Two commissioned clinical trials substantiate the various health claims arising from these studies. Conducted by the Medical University of Vienna and Oregon State University, both clinical trials provided proof positive of XAN Hops Extract’s unrivalled health boosting properties and its outstanding bioavailability.

In addition to reducing the incidence of diseases of the cardiovascular and nervous system or the spread of certain types of cancer, the trials evidenced – and this is a scientific first – DNA protection. Together these properties contribute to a slowing of the aging process. The American clinical study received FDA sanction.

The most recent research endeavours have demonstrated xanthohumol’s effectiveness in regulating the ability to process sugars and fats. XAN Hops Extract can thus help combat obesity and diabetes as well as other disorders prevalent in affluent societies.

XAN Clinical Trial I

The Medical University of Vienna was tasked with the first clinical trial. Prof. Knasmüller and his team conducted a double-blind cross-over placebo controlled study of XAN Hops Extract which measured a broad spectrum of parameters in samples of blood and urine.

This first clinical trial provided scientific proof of the following beneficial health effects:

  • DNA Protection – XAN Hops Extract helps reduce DNA damage and thus guards against a variety of diseases
  • Cell Protection – XAN Hops Extract lessens the risks associated with poor lifestyle choices (smoking, unhealthy diet, stress)
  • Detox – XAN Hops Extract accelerates the body’s own cleansing process and the detoxication of the liver (especially of carcinogens)

The study also demonstrated the superior bioavailability of XAN Hops Extract. When compared with xanthohumol, XAN Hops Extract is absorbed at double the rate of the pure active ingredient.

In addition, the research also established xanthohumol’s capacity to encapsulate tumour cells and thus slow the spread of certain types of cancer.

XAN Clinical Trial II

The purpose of the second clinical trial was to substantiate the excellent results of the first clinical trial and to adduce further proof of XAN Hops Extract’s DNA protective effect. The study, led by Prof. Stevens who enjoys over 30 years of experience in xanthohumol research, was conducted at Oregon State University and sanctioned by the FDA. Furthermore, it had a larger number of test subjects than the first clinical trial. These were divided into three groups, thus enabling the additional gathering of dosage data.

The results showed:

  • DNA Protection – the daily administration of 0.42g XAN Hops Extract significantly reduces DNA damage
  • Bio-availability – a linear dose response between consumption and XAN Hops Extract was noted in the subjects’ plasma

Researchers at Oregon State University have also demonstrated that xanthohumol greatly improves the body’s ability to metabolise sugars and fats, thus helping fight obesity, high cholesterol and diabetes.

XAN Bio-availability

Both XAN clinical trials have provided incontrovertible proof of the superior bio-availability of XAN Hops Extract.

Clinical trial I showed that the same dosage of xanthohumol, when administered in the form of XAN Hops Extract, has twice the protective effect of pure xanthohumol because of XAN Hops Extract’s superior bio-availability.

Clinical trial II analysed the concentrations of XN and its metabolites in the participants’ plasma. XAN Hops Extract was administered on a daily basis over a period for 3 weeks as a beverage at differing daily xanthohumol doses. This resulted in linear dose-dependent plasma concentrations.

Effect of XN on plasma xanthohumol (nM)

  • XAN
  • Placebo

linear dose-plasma concentration effect